StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Total Kite Cell Therapy Product Sales by Year

Total Kite Cell Therapy Product Sales — Rest of World sales ($M) ($M)

Gilead Sciences Total Kite Cell Therapy Product Sales: $335M in FY2025, up 22.3% from a year earlier. That is the highest of the 8 years on record here.

Latest, FY2025
335
Period ended Dec 31, 2025
Change on a year earlier
+22.3%
274 in FY2024
History
8 years
Since FY2018
Sources
6
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-24) ↗

Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTotal Kite Cell Therapy Product Sales — Rest of World sales ($M) ($M)Year on yearSource
FY2025Dec 31, 2025335+22.3%Form 10-K (filed 2026-02-24) ↗
FY2024Dec 31, 2024274+75.6%Form 10-K (filed 2026-02-24) ↗
FY2023Dec 31, 2023156+160.0%Form 10-K (filed 2026-02-24) ↗
FY2022Dec 31, 202260+66.7%Form 10-K (filed 2025-02-28) ↗
FY2021Dec 31, 202136+260.0%Form 10-K (filed 2024-02-23) ↗
FY2020Dec 31, 202010–Form 10-K (filed 2023-02-22) ↗
FY2019Dec 31, 20190–Form 10-K (filed 2022-02-23) ↗
FY2018Dec 31, 20180–Form 10-K (filed 2021-02-25) ↗

Cite this data

StockData. (2026). Gilead Sciences Total Kite Cell Therapy Product Sales ($M), annual FY2018–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/onc-cell-therapy-row

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.